Interventionel undersøgelse af rygereduktion i psykiatri (TABAPSY)
Evaluering af en intervention til at reducere rygning blandt brugere af mental sundhed, der er behandlet i ambulant psykiatri
The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 25 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers. However, tobacco reduction actions specifically targeting these people remain insufficiently developed, particularly in psychiatry where this addiction is often banalized and its treatment neglected.
The objective of this study is to evaluate an intervention ('Tabapsy') co-constructed with mental health services users, mental health professionals, and general practitioners and targeting adult patients followed in ambulatory psychiatry. The main objective is to evaluate the effectiveness of the intervention on short-term smoking cessation (cessation for at least 7 days) among regular smokers at 3 months. Secondary objectives include evaluation of its cost-effectiveness and implementation. To this end, a national cluster-randomized controlled study will be carried out, supplemented by qualitative interviews to study the implementation of the intervention.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 20 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers.
While studies found that people under psychiatric care are as motivated as others to stop smoking, the literature also shows that psychiatric care systems tolerate, underestimate and even encourage smoking among users, despite the fact that psychiatric care, whether at hospital or in an ambulatory setting, is conducive to changes in smoking behaviour and to the implementation of a smoking cessation approach, notably because of anti-smoking regulations in hospitals. In addition, withdrawal symptoms is stronger in this population and smoking cessation would therefore need to be adapted.
Against this backdrop, a smoking cessation intervention ('Tabapsy') was co-constructed with the various stakeholders (users with mental disorders, mental health professionals and general practitioners). Its aim is to encourage and support smoking cessation among people with mental disorders followed in ambulatory psychiatry by medical psychological centers (CMP). It consists of two parts: a campaign to promote smoking cessation within the CMP, and the setting up of an intervention to help people stop smoking. The latter comprises of:
- A general information meeting, to encourage motivation to start smoking cessation;
- An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained;
- Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations;
- Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking.
The intervention also relies on a facilitator specifically recruited to set up the intervention and run the various workshops in the CMP. It is complemented by a website that will contain all the resources and information presented during the meetings/workshops.
The primary objective of the study is to evaluate the effectiveness of the "Tabapsy" intervention on short-term smoking cessation (cessation for at least 7 days) at 3 months among regular smokers followed by adult psychiatric CMPs. Secondary objectives include assessing its cost-effectiveness and implementation.
A cluster-randomized controlled trial will be carried out to evaluate the intervention. The cluster is the "psychiatric sector", i.e., the public care entity responsible for organizing the mental health care of a population within a pre-specified geographical area (including hospital and ambulatory care) in France. A psychiatric sector may include one or multiple CMPs depending on the size of the population it serves. Psychiatric sectors will be randomized into one of two groups (intervention or usual practice).
It will be supplemented by a qualitative study to study the implementation of the intervention.
All regular smokers (at least one cigarette a day) who agree to participate will be asked to complete questionnaires on a WebApp at inclusion, and again at 3 and 6 months. Additional questionnaires will be available in the intervention group. Questions will focus on user characteristics, tobacco consumption, level of nicotine dependence, motivation to quit, use of cessation aids, level of mental and physical well-being, smoking-related knowledge and representations, and in the intervention group, participation in the intervention and satisfaction.
6,250 participants will be included over 12 months, in 22 participating sectors.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Jean-Luc ROELANDT, MD
- Telefonnummer: +33 3 20 43 71 00
- E-mail: jean-luc.roelandt@ghtpsy-npdc.fr
Studiesteder
-
-
-
Armentières, Frankrig, 59280
- Afsluttet
- Public mental health establishment of Lille Metropole (59G16-G17)
-
Armentières, Frankrig, 59280
- Afsluttet
- Public mental health establishment of Lille Metropole (59G21)
-
Bailleul, Frankrig, 59270
- Afsluttet
- Flanders public mental health establishment (59G05/06)
-
Laxou, Frankrig, 54520
- Afsluttet
- Psychotherapeutic center of Nancy (54G02-06)
-
Lille, Frankrig, 59000
- Trukket tilbage
- University Hospital Center of Lille (59G08)
-
Nanterre, Frankrig, 92014
- Afsluttet
- Hospital Care Center of Nanterre (92G10)
-
Paris, Frankrig, 75014
- Afsluttet
- University Hospital Group Paris Neurosciences & Psychiatry (75G04)
-
Rouffach, Frankrig, 68250
- Afsluttet
- Hospital Center of Rouffach (68G02/03)
-
Rouffach, Frankrig, 68250
- Afsluttet
- Hospital Center of Rouffach (68G08/09)
-
Rouffach, Frankrig, 68250
- Afsluttet
- Hospital Center of Rouffach (Pôle LTD - 68G04/05)
-
Saint-Maurice, Frankrig, 94410
- Afsluttet
- Hospitals of Paris Est Val de Marne (94G01)
-
Saint-Maurice, Frankrig, 94410
- Afsluttet
- Hospitals of Paris Est Val de Marne (94G16)
-
Saint-Maurice, Frankrig, 94410
- Afsluttet
- Hospitals of Paris Est Val de Marne (Paris 11)
-
Saint-Maurice, Frankrig, 94410
- Afsluttet
- Hospitals of Paris Est Val de Marne (Paris 12)
-
Saint-Maurice, Frankrig, 94410
- Afsluttet
- Hospitals of Paris Est Val de Marne (Paris Centre)
-
Saint-Venant, Frankrig, 62350
- Afsluttet
- Public mental health establishment of Val de Lys Artois (62G09)
-
Saint-Venant, Frankrig, 62350
- Afsluttet
- Public mental health establishment of Val de Lys Artois (62G12)
-
Saint-Venant, Frankrig, 62350
- Afsluttet
- Public mental health establishment of Val de Lys Artois (Pôle du Ternois)
-
Étampes, Frankrig, 91150
- Rekruttering
- Barthelemy Durand public health establishment (91G05)
-
Kontakt:
- Amina AMRANDI, MD
- Telefonnummer: + 33 1 69 46 86 66
- E-mail: amina.amrandi@eps-etampes.fr
-
Ledende efterforsker:
- Amina AMRANDI, MD
-
-
-
-
-
Saint-Paul, Genforening, 97460
- Afsluttet
- Public mental health establishment of Reunion Island (Pôle Nord)
-
-
-
-
-
Saint-Claude, Guadeloupe, 97122
- Rekruttering
- Public mental health establishment of Guadeloupe (96G06)
-
Kontakt:
- Isabelle DELAROZIERE, MD
- Telefonnummer: +590 5 90 41 48 68
- E-mail: isabelle.delaroziere@epsm-guadeloupe.fr
-
Ledende efterforsker:
- Isabelle DELAROZIERE, MD
-
Saint-Claude, Guadeloupe, 97122
- Rekruttering
- Public mental health establishment of Guadeloupe (96G01)
-
Kontakt:
- Daniel CAPERET, MD
- Telefonnummer: +590 5 90 80 52 62
- E-mail: Daniel.CAPERET@epsm-guadeloupe.fr
-
Ledende efterforsker:
- Magloire MPEMBI, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Regular smokers (at least one cigarette per day)
- Followed in psychiatric ambulatory care at one of the participating sectors' CMPs
- Adults (18 years or older)
- Covered by the statuary health insurance
- Who gave their informed consent to participate to the study
Exclusion Criteria:
- Users under guardianship or legal protection,
- Psychological state incompatible with completing the questionnaire,
- Persons with no command or understanding of the French language
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Intervention arm
Sectors randomized to the intervention group will implement the 'Tabapsy' intervention. |
The Tabapsy intervention consists in a campaign to promote smoking cessation within the CMP, and an intervention to help people stop smoking which comprises of a) A general information meeting; b) An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained; c) Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations; d) Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking. The intervention relies on a facilitator specifically recruited to implement and run the intervention in the CMP. It is complemented by a website that will contain all the resources and information presented dur |
|
Andet: Usual care
Sectors randomized to the control group will continue implementing their usual smoking cessation promotion. |
Usual care corresponds to usual practices regarding smoking cessation activities in participating sectors. Those practices may vary (enquiring whether a patient is a smoker or not, offering smoking cessation if they are or only if the patient asks, etc.) |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Short-term smoking cessation
Tidsramme: 3 months
|
Short-term smoking cessation corresponds to a smoking cessation of at least 7 days, assessed among regular smoker (at least one cigarette a day) included in the study. |
3 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Motivation to stop smoking
Tidsramme: 3 and 6 months
|
The motivation to stop smoking will be assessed using the Q-Mat ("Questionnaire de motivation à l'arrêt du tabac") scale. The computed score ranges from 0 to 20, 20 representing the highest motivation. |
3 and 6 months
|
|
Voluntary quit attempts lasting at least 24 hours in the last 3 months
Tidsramme: 3 and 6 months
|
Number of voluntary quit attempts assessed both as percentage of users reporting at least one quit attempt and mean number of quit attempts per use |
3 and 6 months
|
|
Voluntary quit attempts lasting at least 7 days in the last 3 months
Tidsramme: 3 and 6 months
|
Number of voluntary quit attempts assessed both as percentage of users reporting at least one quit attempt and mean number of quit attempts per user. |
3 and 6 months
|
|
Tobacco consumption
Tidsramme: 3 and 6 months
|
Number of cigarettes smoked per day |
3 and 6 months
|
|
Nicotine dependence
Tidsramme: 3 and 6 months
|
Nicotine dependence will be measured by the 6-question Fagerström test. |
3 and 6 months
|
|
Short-term smoking cessation
Tidsramme: 6 months
|
Short-term smoking cessation corresponds to a smoking cessation of at least 7 days, assessed among regular smoker (at least one cigarette a day) included in the study. |
6 months
|
|
Medium-term smoking cessation
Tidsramme: At 3 and 6 months
|
Medium-term smoking cessation corresponds to a smoking cessation of at least 30 days, assessed among regular smoker (at least one cigarette a day) included in the study. |
At 3 and 6 months
|
|
Use of smoking cessation aids
Tidsramme: 3 and 6 months
|
Number of participants using smoking cessation aids (nicotine replacement therapy and other smoking cessation medications (varenicline or bupropion), electronic cigarettes, and health professionals, assessed together and separately |
3 and 6 months
|
|
Level of mental well-being
Tidsramme: 3 and 6 months
|
Level of mental well-being assessed with a visual analog scale ranging from 1 to 10, 10 representing the highest level of mental well-being |
3 and 6 months
|
|
Level of physical well-being
Tidsramme: 3 and 6 months
|
Level of physical well-being assessed with a visual analog scale ranging from 1 to 10, 10 representing the highest level of physical well-being |
3 and 6 months
|
|
Knowledge and representations surrounding tobacco use
Tidsramme: 3 and 6 months
|
Knowledge and representations surrounding tobacco use will be assessed using a dedicated questionnaire addressed to all the included population as well as to patients who participated to a given workshop |
3 and 6 months
|
|
Cost-effectiveness (short-term)
Tidsramme: A 6 months
|
Incremental cost-effectiveness ratio in cost per additional weaning of at least 7 days. |
A 6 months
|
|
Cost-effectiveness (long-term)
Tidsramme: 6 months
|
Incremental cost-effectiveness ratio in cost per life-year gained over the entire life of users, using extrapolated data and economic modeling (Markov model) to assess lifetime costs and effectiveness 'till all patients in the model are deceased. |
6 months
|
|
Budgetary impact (costs)
Tidsramme: 5 years after hypothetical generalization
|
Direct costs will be calculated with and without the Tabapsy intervention to assess the budgetary impact of its generalization. |
5 years after hypothetical generalization
|
|
Budgetary impact (health benefits)
Tidsramme: 5 years after hypothetical generalization
|
The number of users who have stopped smoking for at least 7 days will be calculated with and without the Tabapsy intervention to assess the health gains associated with its generalization. |
5 years after hypothetical generalization
|
|
Implementation
Tidsramme: 6 months
|
The implementation of the intervention and its components will be assessed using qualitative methods through semi-structured interviews conducted with 25 mental health users et 25 mental health professionnals of the intervention group). |
6 months
|
|
Satisfaction level
Tidsramme: 3 and 6 months
|
Users who participated in one of the components of the intervention will be asked to rate their satisfaction using a visual analog scale ranging from 0 to 10, with 10 corresponding to the highest satisfaction. |
3 and 6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Jean-Luc ROELANDT, MD, GCS-CCOMS & INSERM ECEVE 1123
- Studieleder: Karine CHEVREUL, MD and Pr of public health, Evaluation and research in health services and policies for vulnerable populations, French National Institute for Health and Medical Research (INSERM ECEVE 11 23)
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 2024-A01474-43
- A19017HS (Anden identifikator: Institute for Public Health Research (IRESP))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .